BNP Paribas Financial Markets Has $1.58 Million Holdings in LivaNova PLC (NASDAQ:LIVN)

BNP Paribas Financial Markets boosted its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 22.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 34,185 shares of the company’s stock after acquiring an additional 6,340 shares during the quarter. BNP Paribas Financial Markets’ holdings in LivaNova were worth $1,583,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Algert Global LLC boosted its position in LivaNova by 13.0% during the 4th quarter. Algert Global LLC now owns 118,713 shares of the company’s stock worth $5,498,000 after acquiring an additional 13,696 shares during the period. Aristeia Capital L.L.C. acquired a new stake in LivaNova during the 4th quarter worth about $3,395,000. AXA S.A. acquired a new stake in LivaNova during the 4th quarter worth about $1,662,000. Jane Street Group LLC boosted its position in LivaNova by 45.5% during the 4th quarter. Jane Street Group LLC now owns 193,826 shares of the company’s stock worth $8,976,000 after acquiring an additional 60,613 shares during the period. Finally, Freestone Grove Partners LP acquired a new stake in shares of LivaNova during the 4th quarter valued at about $23,102,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Stock Up 1.3%

Shares of LIVN stock opened at $44.40 on Monday. The stock’s 50 day simple moving average is $38.39 and its 200 day simple moving average is $44.81. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. LivaNova PLC has a twelve month low of $32.48 and a twelve month high of $62.04. The company has a market capitalization of $2.42 billion, a price-to-earnings ratio of 105.71 and a beta of 0.84.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on LIVN shares. StockNews.com lowered LivaNova from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 8th. Wolfe Research lowered LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday, February 26th. The Goldman Sachs Group reduced their price target on LivaNova from $64.00 to $55.00 and set a “buy” rating for the company in a report on Monday, March 3rd. Stifel Nicolaus reduced their price target on LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday, February 26th. Finally, Barclays reduced their price target on LivaNova from $56.00 to $55.00 and set an “equal weight” rating for the company in a report on Thursday, May 8th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $59.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.